Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 22, 2017
Pharmacy Choice - Pharmaceutical News - EyeGate Pharmaceuticals - July 22, 2017

Pharmacy News Article

 7/16/17 - EyeGate Pharmaceuticals

EyeGate Pharmaceuticals

 

EyeGate Pharma is developing a proprietary platform of medicines to treat diseases of the eye using its unique, non-invasive, iontophoretic drug-delivery system called EyeGate II. This proprietary technology platform is based on over 10-years of development at the Bascom Palmer Eye Institute at the University of Miami and has been tested extensively in both preclinical and human studies in Europe. Because of the human eye's special anatomy, effective delivery of medicines to treat chronic disease or diseases in the mid and posterior segments of the eye is less than adequate. They believe the EyeGate II Delivery System will offer both physicians and patients an important new alternative in advancing the treatment of eye disease.

 

Summary

Prior Year Revenue Current Year Revenue Next Year Revenue
Sign up as Investor Sign up as Investor Sign up as Investor
Company Age Employees Sub-Industry
19 years, 6 months 7 Other Biotechnology
Company Type Stock Exchange Stock Symbol
Privately-Held - -

 

Management

 
Director
Thomas Hancock

Thomas E. Hancock Tom has nearly 20 years of venture capital experience and securities analyst experience. 

He currently represents Nexus on the Boards of Presidio Pharmaceuticals, SpectraAnalysis, EyeGate Pharmaceuticals, MyoScience and Magellan Biosciences. Over the last several years, Tom has led investments in numerous successful private companies, including Panacos Pharmaceuticals and Atricure. 

Prior to joining Nexus, Tom was a Managing Director and Senior Equity Analyst at U. S. Bancorp Piper Jaffray covering publicly traded biopharmaceutical companies and drug discovery supplier companies. While at Piper, he published research notes, reports, industry overviews and technology updates for the benefit of the investment community on Gilead Sciences, Tularik, Human Genome Sciences, Millennium Pharmaceuticals, Applied Biosystems, Charles River Laboratories, Invitrogen and Millipore, among others.

 
Director
Paul Chaney

 

 
Director
Morton Goldberg

 

 
Director
Praveen Tyle

 

 
Director
Alain Maiore

 

 
Director
Michael Mullen

 

 
Director
J. Cleftie


© Copyright iCrowdNewswire LLC 2017.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jul 23: REMS Drugs & The Practice of Pharmacy: A Program in Law and Risk Management
Jul 24: What's New? New Treatments for Type 2 Diabetes
Jul 26: Management of Schizophrenia & Acute Agitation
Jul 27: On the Move: A Comprehensive Review of Osteoarthritis, Gout & Rheumatoid Arthritis
Jul 31: Obesity Management: Overview of Pharmacotherapy
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415